SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 3/29/2017 12:52:57 PM - Followers: 712 - Board type: Free - Posts Today: 37

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

FDA Designations:
 


Upcoming Milestones:
 


Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Current Report Filing (8-k) 03/27/2017 11:29:27 AM
CTIX News: Current Report Filing (8-k) 02/16/2017 07:01:38 AM
CTIX News: Quarterly Report (10-q) 02/09/2017 04:04:17 PM
CTIX News: Current Report Filing (8-k) 02/09/2017 09:39:24 AM
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/04/2017 03:58:28 PM
PostSubject
#176593  Sticky Note A little more exposure on CTIX's B-OM results: https://www.insiderfinancial.com nerby 03/28/17 12:22:08 PM
#176575  Sticky Note $CTIX Abstract out on Kevetrin ---- > Title: TheHound 03/28/17 10:12:24 AM
#176409  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase NotAsBigKahuna 03/27/17 10:42:13 AM
#175709  Sticky Note CTIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets sox040713 03/18/17 06:44:12 PM
#175150  Sticky Note NEAR TERM Certainly plenty of catalysts in the BooDog 03/14/17 06:16:45 AM
#174938  Sticky Note B-UP Due Diligence (Rev. 3/10) sox040713 03/10/17 04:08:53 PM
#176684   Thank you. Unfortunately, for now, CTIX has scottsmith 03/29/17 12:52:57 PM
#176683   No pump? LOL. What about the Yo TheMonolith 03/29/17 12:35:14 PM
#176682   Ctix's is worth close to zero. Requires scottsmith 03/29/17 12:29:48 PM
#176681   Everyone has their own reasons for choosing to centillion 03/29/17 12:29:25 PM
#176680   Karen If any group clears up early will the Echo20 03/29/17 12:21:39 PM
#176679   Just an fyi, the placebo arm on Prurisol KarinCA 03/29/17 12:14:41 PM
#176678   prurisol thoughts has any body considered with the untohim 03/29/17 12:06:21 PM
#176677   I think understanding reward is very easy to FlashingLeather 03/29/17 12:02:17 PM
#176676   The price for a priority review voucher keeps baytdr 03/29/17 12:01:32 PM
#176675   Great post SS! Jhawker 03/29/17 12:01:25 PM
#176674   I can't believe people still ask this question. scottsmith 03/29/17 11:37:56 AM
#176673   Perhaps it's purely an issue of risk and FlashingLeather 03/29/17 11:34:04 AM
#176672   I believe you succinctly stated a reasonable position baytdr 03/29/17 11:19:06 AM
#176671   $CTIX NEWS ----> Cellceutix Reports Very Encouraging TheHound 03/29/17 11:11:51 AM
#176670   We may not have pps going our way Jhawker 03/29/17 10:37:37 AM
#176669   I hope everyone reads this post and asks Cowboy5 03/29/17 10:31:53 AM
#176668   Very true. Even if some sort of DaubersUP 03/29/17 10:18:20 AM
#176667   $CTIX - Cellceutix will be presenting new informa TheHound 03/29/17 10:03:39 AM
#176666   excellent post. i shared a very similar experience TheHound 03/29/17 09:57:35 AM
#176665   I think the timing and politics at the baytdr 03/29/17 09:55:24 AM
#176664   True But this is a Bio stock and septmike09 03/29/17 09:45:37 AM
#176663   Cowboy for what it's worth I totally agree JTORENCE 03/29/17 09:40:40 AM
#176662   Wtf! Did you miss the PR earlier this Jhawker 03/29/17 09:36:46 AM
#176661   nothing better than a story that hits close TheHound 03/29/17 09:36:20 AM
#176660   Hearing about all this for 4 years. Still pie Amatuer17 03/29/17 09:27:18 AM
#176659   Very astute post. Eom scottsmith 03/29/17 09:26:56 AM
#176658   My reason for this stock not moving is Cowboy5 03/29/17 09:16:59 AM
#176657   "42 daily is rather challenging for anyone". loanranger 03/29/17 09:04:33 AM
#176656   b up ph2b w/ foam could start as TheHound 03/29/17 08:48:18 AM
#176655   Is anyone aware of any informed estimates of baytdr 03/29/17 08:35:53 AM
#176654   The evolving story of brilacidin as an "anti-inflammatory" mdphd2008 03/29/17 07:55:04 AM
#176653   i think CTIX will triple by noon MXAMDUD 03/29/17 07:34:03 AM
#176650   Another post complaining about FACTS. georgejjl 03/29/17 07:25:09 AM
#176649   right now those who would manipulate the stock untohim 03/29/17 06:21:49 AM
#176648   Speaking of cancer and companies trying to save lives,... TheHound 03/29/17 12:56:25 AM
#176646   A glowing example of a complete lack of NotAsBigKahuna 03/28/17 10:28:40 PM
#176645   picture well painted. TheHound 03/28/17 10:26:16 PM
#176644   thanks. i missed it. TheHound 03/28/17 10:25:15 PM
#176643   While I agree that BP is more interested NotAsBigKahuna 03/28/17 10:19:33 PM
#176642   Another presentation with mice data. What is use of Amatuer17 03/28/17 10:00:28 PM
#176641   While some find a well-administered occasional enema somewhat NotAsBigKahuna 03/28/17 09:57:07 PM
#176640   Yes, Leo alluded to oral Brilacidin forumulations for biodoc 03/28/17 09:54:37 PM
#176639   George ctix will triple by April 15? Good luck youssef 03/28/17 09:39:14 PM
#176638   1 week from today homie... TheHound 03/28/17 09:38:57 PM
#176637   Tuesday April 4, 2017 3221 / 22 - georgejjl 03/28/17 09:27:16 PM
#176636   interesting. appreciate the info yo. TheHound 03/28/17 08:53:28 PM
#176635   Planned oral formulations of Brilacidin georgejjl 03/28/17 08:50:04 PM
#176634   We need to get through the 50 DMA septmike09 03/28/17 08:28:44 PM
#176633   Haven't heard or seen a pill form, but F1ash 03/28/17 08:26:05 PM
#176632   That is certainly possible. Someone seeing the BooDog 03/28/17 08:18:30 PM
PostSubject